Leonard Zehr, Author at BioTuesdays

This Week's Feature

POINT Biopharma creating platform for next-generation radiopharmaceuticals

POINT Biopharma Global (NASDAQ:PNT) is accelerating the development of precision medicines for the treatment of cancer, with a late- and early-stage pipeline of radiopharmaceuticals, a technology platform for pipeline...

January 18, 2022

Features

ENDRA’s TAEUS enhancing ultrasound to measure fatty liver disease NAFLD-NASH

ENDRA Life Sciences (NASDAQ:NDRA) has developed a novel assessment tool – Thermo Acoustic Enhanced Ultrasound (TAEUS) – to enhance existing ultrasound systems and provide capabilities that are available with MRI, but at...

January 11, 2022

Features

Illuminate Health offering pharmacist-led virtual medication management

Closely-held Illuminate Health is leveraging a technology-enabled continuous medication management platform to help patients optimize medications at home to improve treatment adherence and reduce hospitalizations.

January 4, 2022

This Week's Feature

Annovis Bio improving information highway of nerve cells to treat AD, PD

Annovis Bio (NYSE:ANVS) is developing a lead drug candidate, ANVS401, to inhibit more than one neurotoxic protein, improving the information highway of nerve cells, known as axonal transport, for the treatment of...

December 14, 2021

Features

Rani developing technology for oral delivery of injectable biologics

Rani Therapeutics (NASDAQ:RANI) is developing a disruptive technology to solve the problem of converting biologic injectable drugs, including antibodies, peptides and proteins, into oral therapies with its RaniPill that...

December 7, 2021

Features

Fabian Gerlinghaus talks up the power of the Cellares Cell Shuttle

As a co-founder and CEO of closely-held Cellares, which is pioneering an automated approach to cell therapy manufacturing, Fabian Gerlinghaus, an aerospace engineer by training, made the switch to biotech eight years...

November 30, 2021

Features

Genocea’s pioneering next generation neoantigen targets T-cell therapy

Genocea Biosciences (NASDAQ:GNCA) is on a mission to make better cancer immunotherapies for patients, beginning with better target discovery.

November 23, 2021

Executive Moves

Labster names Hope Frank as CMO

Closely-held Labster, a virtual learning platform for students, named Hope Frank as chief marketing officer as part of its continued mission to bring accessible and transformative STEM education (science, technology...

November 17, 2021

Features

FSD Pharma developing treatments for neurodegenerative, neuropsychiatric diseases

FSD Pharma (CSE, NASDAQ:HUGE; FRA:0K9A) is developing novel solutions to bring cutting-edge neurodegenerative and mental health therapies to market, with a focus on some of the hard-to-treat diseases, such as major...

November 16, 2021

Features

Titan Pharmaceuticals, UW treating chronic itch with ProNeura implant

As a research assistant professor at the Department of Pharmacology at the University of Washington, Dr. Ben Land, Ph.D. is broadly interested in how cannabinoids and opioids mediate pain and reward. But in a...

November 9, 2021

Author - Leonard Zehr

POINT Biopharma creating platform for next-generation radiopharmaceuticals

ENDRA’s TAEUS enhancing ultrasound to measure fatty liver disease NAFLD-NASH

Illuminate Health offering pharmacist-led virtual medication management

Annovis Bio improving information highway of nerve cells to treat AD, PD

Rani developing technology for oral delivery of injectable biologics

Fabian Gerlinghaus talks up the power of the Cellares Cell Shuttle

Genocea’s pioneering next generation neoantigen targets T-cell therapy

Labster names Hope Frank as CMO

FSD Pharma developing treatments for neurodegenerative, neuropsychiatric diseases

Titan Pharmaceuticals, UW treating chronic itch with ProNeura implant

General

More

Sign up for the BioTuesdays weekly newsletter